2020

• Cyhoeddwydjava.lang.NullPointerException
• Cyhoeddwydjava.lang.NullPointerException

2019

• Cyhoeddwydjava.lang.NullPointerException

2018

• Cyhoeddwydjava.lang.NullPointerException
• Cyhoeddwydjava.lang.NullPointerException
• Cyhoeddwydjava.lang.NullPointerException

2017

• Cyhoeddwydjava.lang.NullPointerException

2015

• Cyhoeddwydjava.lang.NullPointerException
• Cyhoeddwydjava.lang.NullPointerException

2011

• Cyhoeddwydjava.lang.NullPointerException

2010

• Cyhoeddwydjava.lang.NullPointerException
• Cyhoeddwydjava.lang.NullPointerException

2009

• Cyhoeddwydjava.lang.NullPointerException
• Cyhoeddwydjava.lang.NullPointerException
• Cyhoeddwydjava.lang.NullPointerException
• Cyhoeddwydjava.lang.NullPointerException

2007

• Cyhoeddwydjava.lang.NullPointerException

2006

• Cyhoeddwydjava.lang.NullPointerException

2005

• Cyhoeddwydjava.lang.NullPointerException

2004

• Cyhoeddwydjava.lang.NullPointerException

2003

• Cyhoeddwydjava.lang.NullPointerException

2002

• Cyhoeddwydjava.lang.NullPointerException
• Cyhoeddwydjava.lang.NullPointerException

2001

• Cyhoeddwydjava.lang.NullPointerException
• Cyhoeddwydjava.lang.NullPointerException

1999

• Cyhoeddwydjava.lang.NullPointerException

1998

• Cyhoeddwydjava.lang.NullPointerException

1994

• CyhoeddwydImmunocytochemical techniques applied to meiotic chromosomes
  Heyting, C., Dietrich, A. J., de Jong, J. H. & Hartsuiker, E., 1994, Chromosome Analysis Protocols. Gosden, J. R. (gol.). Cyfrol 29. t. 287-302 (Methods in Molecular Biology).
  Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod › adolygiad gan gymheiriaid

• KESS II MRes with NWCR - BUK2E091

  01/10/2022 – 31/10/2023 (Wrthi'n gweithredu)

• KESS II Mres with NWCR in Molecular Medicine BUK2231

  01/10/2022 – 31/10/2023 (Wrthi'n gweithredu)

• KESS II MRes with North West Cancer Research BUK2222

  01/01/2021 – 31/01/2022 (Wedi gorffen)

• KESS II MRes with North West Cancer Research BUK2224

  01/01/2021 – 28/02/2023 (Wedi gorffen)

• KESS II Phd with Tenovus BUK2E004

  01/03/2020 – 22/03/2023 (Wedi gorffen)

• KESS II MRes with North West Cancer Research- BUK2176

  01/10/2019 – 30/09/2021 (Wedi gorffen)

• KESS II MRes with North West Cancer Research- BUK2175

  01/10/2018 – 31/07/2020 (Wedi gorffen)

• KESS II MRes with North West Cancer Research- BUK2177

  01/10/2018 – 28/08/2020 (Wedi gorffen)

• KESS II MRes with North West Cancer Research- BUK2178

  01/10/2018 – 30/06/2022 (Wedi gorffen)

• KESS II Phd with Tenovus Cancer Care Ltd- BUK2128

  01/11/2017 – 30/09/2021 (Wedi gorffen)

• Quantitative detection of DNA damage and nucleotides using LC/MS/MS

  01/01/2016 – 30/04/2016 (Wedi gorffen)

• Genome-wide analysis of topoisomerase removal pathways

  01/09/2015 – 01/08/2019 (Wedi gorffen)

• Wales Cancer Research Centre

  01/04/2015 – 01/08/2019 (Wedi gorffen)

• Funding for equipment

  01/01/2015 – 28/02/2023 (Wedi gorffen)

• Role of Mre11 nuclease activity in replication fork progression

  01/11/2014 – 31/10/2015 (Wedi gorffen)

• Role of DNA repair in resisting treatment with Gemcitabine and other analogues

  01/01/2014 – 30/06/2017 (Wedi gorffen)

• NWCR Research Fellow in Cancer Biology

  23/09/2013 – 01/08/2019 (Wedi gorffen)

• The role of nucleotide excision repair in providing resistance to the nucleoside

  01/06/2013 – 10/11/2017 (Wedi gorffen)

• The role of the Mre11 nuclease activity in resistance to cancer drugs

  01/12/2011 – 30/11/2013 (Wedi gorffen)

• Genome-wide analysis of topoisomerase removal after camptothecin treatment

  01/10/2011 – 31/12/2014 (Wedi gorffen)

• The NISCHR Cancer Genetics Biomedical Research Unit

  01/03/2011 – 01/08/2019 (Wedi gorffen)

• Identification and analysis of DNA repair mechanisms that contribute to resistance against nucleoside analogues

  01/10/2010 – 30/09/2014 (Wedi gorffen)

• Analysis of MRN-dependent and -independent topoisomerase removal mechanisms: implications for resistance against camptothecin and etoposide derivatives

  01/09/2010 – 31/08/2016 (Wedi gorffen)